Michael Celano - Jan 22, 2025 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Role: Chief Financial Officer
Signature: /s/ Jennifer Johansson, Attorney-in-fact
Stock symbol: LRMR
Transactions as of: Jan 22, 2025
Transactions value $: $0
Form type: 4
Date filed: 1/24/2025, 04:15 PM
Previous filing: Jan 19, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LRMR	Common Stock	Award	$0	+34.2K	+23.74%	$0.00	178K	Jan 22, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LRMR	Stock Option (Right to Buy)	Award	$0	+205K		$0.00	205K	Jan 22, 2025	Common Stock	205K	$3.46	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F2	The option vests 25% on January 22, 2026, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.